Ann: CEO's address to AGM , page-2

Still reading through this very carefully, but so far very good explanation of how this shapes up.

The full explanation of how the new Oral NNZ-2566 will progress for Concussion and RETTS is very exciting.

They have clearly stated that it has a really good safety profile. TICK. A really long shelf life and easy to administer. TICK. Fast Track trials that are simple to run with easy access to patients. Very low efficacy levels required. TICK Easy and cheap to run the TRIALS. and Short Duration trials to Complement FDA FAST TRACK>

Short version is. You will never ever see another Drug fly through human Trials as quickly and cheaply as Oral NNZ-2566.

And further that people like RETTS Patient Support Groups are in there lending a hand.

Not to mention timing is perfect for FDA Big Pharma and BIG Bio to be very interested.

This all goes to show why BELLS have rated this at .17 cents.